Pancreatic AdenocarcinomaPARANCT06815172
PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.
An observational study of Pancreatic Adenocarcinoma, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.
Trial summary
The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. Read more about this study
- Who is it for?
- Ages 30 to 90 years
- Conditions the study is for
- Pancreatic Adenocarcinoma
- How many people
- 500 participants
- Where
- 1 siteItaly
- Study dates
- 28 May 2020to Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The maximum duration of the enrollment period will be 32 years, in which 100 participants from Group A and 400 participants from Group B (previously enrolled in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - Study of risk factors of biliary neoplasms) with code 111/2013/UOSS evaluated in the meeting of the Ethics Committee on 19/11/2013 will be recruited. In each case, four hospital checks will be matched, in frequency matching by sex and five-year age group. The choice of this ratio between Group A and Group B (1:4) is justified by the desire to maximize the statistical power of the study.
Who may be able to join
- Incident cases (new diagnosis) of histologically diagnosed pancreatic adenocarcinoma afferent to the Medical Oncology Unit Prof. Ardizzoni
- Age 30-90 years
- Ability to complete the questionnaire
- Ability to read and understand Italian
- Signing the informed consent form
- Patients admitted to the S.Orsola-Malpighi Polyclinic in the ophthalmology, gynecology and urology departments with a diagnosis of cataracts, uterine fibroids and prostate adenoma previously included in the CARA study.
Show all 10Show fewer
- Age 30-90 years
- Ability to complete the questionnaire
- Ability to read and understand Italian
- Signing the informed consent form
Who cannot join
- 1. Prevalent cases of the pathology under study
- Group B
- Patients with pancreatic adenocarcinoma
- Patients with a history of malignant neoplastic pathologies
- Patients suffering from diseases associated with exposure to asbestos: pleuropatias (parietal plaques, diffuse visceral thickening, recurrent effusions and round atelectasis) and pulmonary diseases (alveolitis and asbestosis)
- Patients in danger of life or hospitalized waiting to undergo surgery for pathologies other than those of inclusion
Trial locations and contacts
1 site in 1 country.
About this study
Official title: PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos): Study of Risk Factors for Exocrine Pancreatic Neoplasms.
The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. The data collected will be used to generate specific hypotheses on the possible environmental and occupational determinants of the disease.
The study aims to evaluate:
Read more
- To evaluate the exposure to asbestos occurred during life, through the use of a standardized questionnaire to be administered to incident cases (newly diagnosed) of histologically diagnosed pancreatic adenocarcinoma afferent to the Medical Oncology Unit Prof. Ardizzoni in Group A, the exposure to asbestos occurred during the course of life;
- To produce quantitative estimates of the risk of pancreatic adenocarcinoma associated with asbestos exposure.
2.3. To evaluate the presence of asbestos fibers directly on histological sections of pancreatic cancer of patients exposed to asbestos and undergoing surgery.
Read the detailed description
Pancreatic adenocarcinoma (PDAC) ranks fourth among the causes of cancer death in Western countries, with an incidence almost comparable to mortality. The only therapeutic option with curative intent is surgery, but about 80% of subjects diagnosed with this neoplasm are not candidates for surgery due to the presence of distant metastases (stage IV according to the TNM system) or in the case of locally advanced disease (stage III), with an overall survival at 5 years of less than 10%.
Numerous risk factors have been related to the genesis of PDAC both environmental and genetic.
Environmental factors include cigarette smoking, dietary habits such as high intake of animal proteins and fats, high salt consumption, dehydrated foods, smoked meat, fried foods and smoked sugar, obesity, consumption of high amounts of alcohol, occupational exposure to chlorinated hydrocarbons, chronic pancreatitis and type II diabetes mellitus.
However, most of them are non-specific and there is often no concordance between the different studies conducted to evaluate them.
The role of asbestos exposure as an environmental risk factor in the etiopathogenesis of pancreatic cancer has been poorly investigated to date and with discordant results.
However, as previously demonstrated, asbestos, once inhaled, can enter the lymphatic circulation and therefore the bloodstream by accumulating in the tissues. In particular, a deposit of asbestos fibers in the liver has been demonstrated with the possibility of triggering chronic inflammatory mechanisms underlying the carcinogenic process. Similarly to what has already been demonstrated on the association between occupational exposure to asbestos and the risk of intrahepatic cholangiocarcinoma, this observational study aims to evaluate a possible correlation between this environmental risk factor and pancreatic cancer.
Materials and methods A prospective non-pharmacological single-center observational study will be carried out.
A total of 500 subjects will be involved between Group A and Group B, distributed as follows:
- 100 subjects of Group A will be patients seen on an outpatient basis and suffering from pancreatic adenocarcinoma with histological confirmation, contacted both during hospitalization and during outpatient or day service access;
- 400 subjects of Group B will be patients already included as controls in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - code 111/2013/UOSS evaluated in the meeting of the Ethics Committee of 19/11/2013) admitted to the Polyclinic in the ophthalmology, urology and gynecology departments not affected by the pathology under study, nor by pathologies associated with exposure to asbestos.
Upon obtaining informed consent, all subjects in Group A will be administered a standardized questionnaire (once per patient), containing questions from the ReNaM questionnaire (National Mesothelioma Registry), the work history of the subjects and some questions related to known risk factors.
Descriptive population statistics will be presented, stratifying according to case or control status. To estimate the strength of the association between asbestos exposure and pancreatic cancer risk, uni- and multivariate logistic models will be conducted.
On 30 cases subjected to the ReNaM questionnaire, the presence of asbestos fibers directly on histological sections of pancreatic cancer, obtained following surgical resection for curative therapeutic purposes according to the standard of care, will be evaluated.
Samples will be evaluated using light microscopy and scanning electron microscopy with attached chemical microprobe to highlight the presence of fibers within the tumor tissue.
- Conditions
- Pancreatic Adenocarcinoma
- Keywords
- asbesto, cancer, risk factor, pancreatic adenocarcinoma
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group A | 100 subjects will be patients seen on an outpatient basis and suffering from pancreatic adenocarcinoma with histological confirmation, contacted both during hospitalization and during outpatient access or in day service | |
| Group B | 400 subjects will be patients already included as controls in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - code 111/2013/UOSS evaluated in the meeting of the Ethics Committee of 19/11/2013) admitted to the Polyclinic in the ophthalmology, urology and gynecology departments not affected by the pathology under study, nor by pathologies associated with exposure to asbestos. |
What is being measured
The primary outcome is the main question the study is designed to answer.
primary objective
The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. The data collected will be used to generate specific hypotheses on the possible environmental and occupational determinants of the disease.
Measured: From enrollment to the administration of the standardized questionnaire (once per patient), containing questions from the ReNaM (National Mesothelioma Registry) for up to 60 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Feb 2025
- Study start28 May 2020
- Primary completionSep 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by IRCCS Azienda Ospedaliero-Universitaria di BolognaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
- Responsible party
- Sponsor
- Investigators
- GIOVANNI BRANDI, MD, PHD, Principal investigator, University of Bologna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06815172
- Sponsor's protocol ID
- PARA
- Other IDs
- RC-2022-2773381
- Acronym
- PARA
- Status last verified
- Dec 2024
- First submitted
- 10 Jan 2025
- Last updated
- 7 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos): Study of Risk Factors for Exocrine Pancreatic Neoplasms.
- ClinicalTrials.gov ID
- NCT06815172
- Acronym / sponsor ID
- PARA / PARA
- Conditions
- Pancreatic Adenocarcinoma
- Keywords
- asbesto, cancer, risk factor, pancreatic adenocarcinoma
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity, hospital or other
- Collaborators
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
- Study start
- 28 May 2020 (actual)
- Primary completion
- Sep 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 7 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. The data collected will be used to generate specific hypotheses on the possible environmental and occupational determinants of the disease.
The study aims to evaluate:
- To evaluate the exposure to asbestos occurred during life, through the use of a standardized questionnaire to be administered to incident cases (newly diagnosed) of histologically diagnosed pancreatic adenocarcinoma afferent to the Medical Oncology Unit Prof. Ardizzoni in Group A, the exposure to asbestos occurred during the course of life;
- To produce quantitative estimates of the risk of pancreatic adenocarcinoma associated with asbestos exposure.
2.3. To evaluate the presence of asbestos fibers directly on histological sections of pancreatic cancer of patients exposed to asbestos and undergoing surgery.
Detailed description
Pancreatic adenocarcinoma (PDAC) ranks fourth among the causes of cancer death in Western countries, with an incidence almost comparable to mortality. The only therapeutic option with curative intent is surgery, but about 80% of subjects diagnosed with this neoplasm are not candidates for surgery due to the presence of distant metastases (stage IV according to the TNM system) or in the case of locally advanced disease (stage III), with an overall survival at 5 years of less than 10%.
Numerous risk factors have been related to the genesis of PDAC both environmental and genetic.
Environmental factors include cigarette smoking, dietary habits such as high intake of animal proteins and fats, high salt consumption, dehydrated foods, smoked meat, fried foods and smoked sugar, obesity, consumption of high amounts of alcohol, occupational exposure to chlorinated hydrocarbons, chronic pancreatitis and type II diabetes mellitus.
However, most of them are non-specific and there is often no concordance between the different studies conducted to evaluate them.
The role of asbestos exposure as an environmental risk factor in the etiopathogenesis of pancreatic cancer has been poorly investigated to date and with discordant results.
However, as previously demonstrated, asbestos, once inhaled, can enter the lymphatic circulation and therefore the bloodstream by accumulating in the tissues. In particular, a deposit of asbestos fibers in the liver has been demonstrated with the possibility of triggering chronic inflammatory mechanisms underlying the carcinogenic process. Similarly to what has already been demonstrated on the association between occupational exposure to asbestos and the risk of intrahepatic cholangiocarcinoma, this observational study aims to evaluate a possible correlation between this environmental risk factor and pancreatic cancer.
Materials and methods A prospective non-pharmacological single-center observational study will be carried out.
A total of 500 subjects will be involved between Group A and Group B, distributed as follows:
- 100 subjects of Group A will be patients seen on an outpatient basis and suffering from pancreatic adenocarcinoma with histological confirmation, contacted both during hospitalization and during outpatient or day service access;
- 400 subjects of Group B will be patients already included as controls in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - code 111/2013/UOSS evaluated in the meeting of the Ethics Committee of 19/11/2013) admitted to the Polyclinic in the ophthalmology, urology and gynecology departments not affected by the pathology under study, nor by pathologies associated with exposure to asbestos.
Upon obtaining informed consent, all subjects in Group A will be administered a standardized questionnaire (once per patient), containing questions from the ReNaM questionnaire (National Mesothelioma Registry), the work history of the subjects and some questions related to known risk factors.
Descriptive population statistics will be presented, stratifying according to case or control status. To estimate the strength of the association between asbestos exposure and pancreatic cancer risk, uni- and multivariate logistic models will be conducted.
On 30 cases subjected to the ReNaM questionnaire, the presence of asbestos fibers directly on histological sections of pancreatic cancer, obtained following surgical resection for curative therapeutic purposes according to the standard of care, will be evaluated.
Samples will be evaluated using light microscopy and scanning electron microscopy with attached chemical microprobe to highlight the presence of fibers within the tumor tissue.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | – | –100 subjects will be patients seen on an outpatient basis and suffering from pancreatic adenocarcinoma with histological confirmation, contacted both during hospitalization and during outpatient access or in day service |
| Group B | – | –400 subjects will be patients already included as controls in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - code 111/2013/UOSS evaluated in the meeting of the Ethics Committee of 19/11/2013) admitted to the Polyclinic in the ophthalmology, urology and gynecology departments not affected by the pathology under study, nor by pathologies associated with exposure to asbestos. |
Who may qualify
- Ages
- 30 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The maximum duration of the enrollment period will be 32 years, in which 100 participants from Group A and 400 participants from Group B (previously enrolled in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - Study of risk factors of biliary neoplasms) with code 111/2013/UOSS evaluated in the meeting of the Ethics Committee on 19/11/2013 will be recruited. In each case, four hospital checks will be matched, in frequency matching by sex and five-year age group. The choice of this ratio between Group A and Group B (1:4) is justified by the desire to maximize the statistical power of the study.
Key inclusion criteria (10 listed)
- Incident cases (new diagnosis) of histologically diagnosed pancreatic adenocarcinoma afferent to the Medical Oncology Unit Prof. Ardizzoni
- Age 30-90 years
- Ability to complete the questionnaire
- Ability to read and understand Italian
- Signing the informed consent form
Key exclusion criteria (6 listed)
- 1. Prevalent cases of the pathology under study
- Group B
- Patients with pancreatic adenocarcinoma
- Patients with a history of malignant neoplastic pathologies
- Patients suffering from diseases associated with exposure to asbestos: pleuropatias (parietal plaques, diffuse visceral thickening, recurrent effusions and round atelectasis) and pulmonary diseases (alveolitis and asbestosis)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
primary objective
Time frame: From enrollment to the administration of the standardized questionnaire (once per patient), containing questions from the ReNaM (National Mesothelioma Registry) for up to 60 days.
The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. The data collected will be used to generate specific hypotheses on the possible environmental and occupational determinants of the disease.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Feb 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Pancreatic Adenocarcinoma
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GIOVANNI BRANDI, MD, PHD principal investigator
University of Bologna
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Adenocarcinoma, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
primary objective (time frame: From enrollment to the administration of the standardized questionnaire (once per patient), containing questions from the ReNaM (National Mesothelioma Registry) for up to 60 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Feb 2025.